Dear Colleagues,

Liver disease and cirrhosis are the sixth most common cause of death in adults between the ages of 25 and 64. Drug-induced hepatitis is a type of liver disease and a leading cause of acute liver failure. Drug-induced, immune-mediated liver injury is the most common hepatic, immune-mediated liver disease and is a common reason an approved medication being removed from the consumer market. Current evidence suggests that susceptible individuals can develop drug-induced, immune-mediated liver injury after receiving halogenated anesthetics, antiseizure medications, antibiotics, antivirals, antihypertensives, or nonsteroidal anti-inflammatory drugs. A major challenge to understanding the pathogenesis of drug-induced, immune-mediated liver injury is its diverse presentations, which can range from toxic hepatitis-induced acute liver failure to immune-mediated hepatitis with autoimmune features. Precise understanding of the molecular mechanisms of drug-induced, immune-mediated liver injury through basic, translational, and clinical studies is critical in order to reduce significant morbidity in patients, unanticipated costs to patients and hospitals, and to completely address this disease. The key molecular mechanisms that initiate drug-induced, immune-mediated liver injury have been uncovered, and the mechanisms that modulate disease severity are now being discovered.  Our goal in this Special Issue is to convey the mechanisms that regulate the severity of DIH using in vitro models, animal models, in silico studies, and human studies that might uncover therapeutic targets or mechanisms that regulate morbidity or mortality of drug-induced, immune-mediated liver injury in patients.

Dr. Dolores B. Njoku
Dr. Munish Puri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.